The search for a noncalcifying tissue material to be used for valve replacement application continues to be a field of extensive investigation. A series of porcine pericardial membranes was prepared by modifying the glutaraldehyde - treated tissues with albumin and subsequently immobilizing bioactive molecules like PGE1, PGI2 or heparin via the carbodiimide functionalities. The in vitro calcification and collagenase degradation of these modified tissues were studied as a function of exposure time. Furthermore, the biocompatibility aspects of such novel interfaces were established by platelet adhesion and fibrinogen adsorption.
The results reported in this article propose that the treatment with antiplatelet agents such as albumin, heparin and prostaglandins (PGE1 or PGI2) change the surface conditioning of pericardial tissues, suggesting a possible role of deposited serum components in affecting mineralization process on bioprosthesis. Therefore, it is worthy to hypothesize that besides inhibiting the accumulation of calcium in the devitalized cells, the early formation of a conditioning layer on the bioprosthesis surface may affect salt precipitations, determining the propensity of the implant to calcify. More detailed studies are needed to understand the involvement of plasma proteins and cellular components of the recipient blood in tissue-associated calcification.
SchoenF.J.Cardiac valve bioprostheses: review of clinical status and contemporary biomaterials issues. J Biomed Mater Res Appl Biomater1987; 21: 91–117.
2.
FerransV.J., BoyceS.W., BillinghamM.E., JonesM., IshiharaT., RobertsW.C.Calcific deposits in porcine bioprostheses. Structure and pathogenesis. Am J Cardiol1980; 46: 721–34.
3.
LevyR.J., SchoenF.J., LevyT.T., NelsonA.C., HowardS.L., OshryL.J.Biologic determinants of dystrophic calcification and osteocalcin deposition in glutaraldehyde preserved porcine aortic valve leaflets implanted subcutaneously in rats. Am J Pathol1983; 113: 143–55.
4.
GolombG., SchoenF.J., SmithM.S., LindenJ., DixonM., LevyR.J.The role of glutaraldehyde-induced crosslinks in calcification of bovine pericardium used in cardiac valve bioprostheses. Am J Pathol1987; 127: 122–30.
WebbC.L., SchoenF.J., FlowersW.E., AlfreyA.C., HortonC., LevyR.J.Inhibition of mineralization of glutaraldehyde-pretreated bovine pericardium by AI CI3. Am J Pathol1991; 138: 971–81.
7.
ChandyT., KumarB.A., SharmaC.P.Inhibition of in vitro calcium phosphate precipitation in the presence of polyurethane via surface modification and drug delivery. J Appl Biomaterials1994; 5: 245–54.
8.
VasudevS.C., ChandyT., SharmaC.P.Influence of polyethylene glycol graftings on the in vitro degradation and calcification of bovine pericardium. J Biomat Appl1997; 11: 430–52.
9.
VasudevS.C., ChandyT.Effect of alternative crosslinking techniques on the enzymatic degradation of bovine pericardia and their calcification. J Biomed Mater Res, 1997; 35: 357–69.
10.
GolombG.Controlled release of diphosphonates from synthetic polymers to inhibit calcification. J Biomat Appl, 1987; 2: 266–89.
11.
ChandyT., MohantyM., JohnA.Structural studies on bovine bioprosthetic tissues and their in vivo calcification: prevention via drug delivery. Biomaterials1996; 17: 577–86.
12.
VyavahareN.R., HirshD., LernerE.Prevention of calcification of glutaraldehyde-crosslinked porcine aortic cusps by ethanol preincubation. Mechanistic studies of protein structure and water-biomaterial relationships. J Biomed Mater Res1998; 40: 577–85.
13.
RosanovaI.B., LanskayaI.M., SevastianovV.I.Calcium-binding capacity of serum proteins after contact with biomaterials (in vitro experiments). Biomater Liv Sys Interact1993; 1: 13–18.
14.
LevyR.J., SchoenF.J., AndersonH.C.Cardiovascular implant calcification: a survey and update. Biomaterials1991; 12: 707–14.
15.
BuckwalterJ.A., GlimcherM.J., CooperR.R., ReckerR.“Bone biology” Part 1: Structure, blood supply, cells matrix and mineralization. J Bone Joint Surg1995; 77A: 1256–75.
16.
ChandyT., SharmaC.P.Protein-polymer interaction-changes with plasma components, vitamins and antiplatelet drugs at the interface. Polym Plast Tech Eng1987; 26: 143–227.
17.
MantovaniD., BedardE., MaroisM., GuidoinR., LarocheG.Lipid uptake in ePTFE arterial prostheses implanted in humans. J Mater Sci Mater Med1996; 7: 40–5.
18.
VromanL., AdamsA.L., FischerG.C., MunozP.C., StanfordM.Proteins, plasma and blood in narrow spaces of clot-promoting surfaces, Adv Chem Ser1982: 199: 266–76.
19.
ParkK., MosherD.E., CooperS.L.Acute surface-induced thrombosis in the canine ex vivo model: importance of protein composition of the initial monolayer and platelet activation. J Biomed Mater Res1986; 20: 589–612.
ChandyT., SharmaC.P.Bioactive molecules immobilized to liposome-modified albumin blended chitosan membranes-Antithrombotic and permeability properties, J Colloid Interface Sci1989; 130: 331–40.
22.
ChandyT., VasudevS.C., RaoG.H.R.Changes in pericardial calcification due to antiplatelet agents: In vitro studies, Artif Org1998: 22: 666–71.
23.
ChandyT., VasudevS.C., SharmaC.P.Changes in polyurethane calcification due to antibiotics. Artif Organs1996; 20: 752–60.
24.
PackhamM.A.Platelet function inhibitors, Thromb Haemostats (Stuttgart)1983: 50: 610–9.
25.
EbertC., McReaJ., KimS.W.Controlled release of antithrombotic agents from polymer matrices, in Controlled release of Bioactive Materials, 1980; 107–22.
BaillyA.L., LaurentA., LuH.Fibrinogen binding and platelet retention: relationship with the thrombogenecity of catheters. J Biomed Mater Res1996; 30: 101–8.
28.
GolombG., WagnerD.Development of a new in vitro model for studying implantable polyurethane calcification. Biomaterials1991; 12: 387–405.
29.
KimS.W., WisniewskiS., LeeE.S., WinnM.L.Role of protein and fatty acid adsorption on platelet adhesion and aggregation at the blood-polymer interface. J Biomed mater Res1977; 11: 23–31.
30.
GlasmacherB., DeiwickM., ReulH., KneschH., KeusD., RauG.A new in vitro test method for calcification of bioprosthetic heart valves. Int J Artif Organs1997; 20: 267–71.
31.
ChandyT., SharmaC.P.Anesthetic and ferric-magnesium ion combinations as calcium antagonists for glutaraldehyde-treated pericardial tissue. Clin Mater1994; 17: 165–72.
32.
ThomaR.J.Poly(ether) urethane reactivity with metal ion in calcification and environmental stress, cracking. J Biomater Applications1987; 1: 449–86.
33.
JangI., GoldH.K., ZiskindA.A., LeinbarchR.C., FallonJ.T., CollenD.Prevention of platelet rich arterial thrombosis by selective thrombin inhibition. Circulation1990; 81: 219–25.
34.
TakemotoY., MatsudaT., OzekiE., KishimotoT., MaekawaM., AkutsuT.Development of a novel biocompatibilty test method based on intracellular calcium ion mobilization. Trans Am Soc Artif Organs1989; 35: 325–7.
35.
AvdoninP.V., CheglakovI.B., BoogryE.M., Svitina-UlitinaI.V., MazaevA.V., TkachukV.A.Evidence for the receptor-operated calcium channels in human platelet plasma membrane. Thromb Research1987; 46: 26–37.
36.
AbolhodaA., YuS., OyarzunJ.R.No-React detoxification process: A superior anticalcification method for bioprostheses. Ann Thorac Surg1996; 62: 1724–30.
37.
NojiriC., KidoT., SugiyamaT.Can heparin-immobilized surfaces maintain nonthrombogenic activity during in vivo long-term implantation?Am Soc Artif Intern Org J1996; 42: M468–75.
38.
Van DeldenC.J., EngbersG.H.M., FeijenJ.The effect of protein adsorption on the anticoagulant activity of surface-immobilized heparin. J Biomate Sci Polym Ed1996; 7: 727–40.
39.
Van DeldenC.J., EngbersG.H.M., FeijenJ.The interactions between antithrombin III, thrombin and surface-immobilized heparin. J Biomater Sci Polym Ed1996; 7: 989–1004.
